Arrowhead Research | ARWR - Assets

Stock Price
27.80
Daily Change
-1.28 -4.40%
Monthly
61.53%
Yearly
27.76%
Q3 Forecast
28.84

Arrowhead Research reported $1.38B in Assets for its fiscal quarter ending in June of 2025.



Financials
Stock Price USD
Assets USD 1.38B
Cash and Equivalent USD 129.79M
Current Assets USD 946.92M
Current Liabilities USD 194.53M
Debt USD 388.24M
EBIT USD -165.55M
EBITDA USD -159.33M
Employees 609
EPS Earnings Per Share USD -1.26
Equity Capital and Reserves USD 522.31M
Gross Profit on Sales USD 27.77M
Interest Expense on Debt USD 24.38M
Interest Income USD 9.62M
Loan Capital USD 200.33M
Market Capitalization USD 3.51B
Net Income USD -175.24M
Operating Expenses USD 193.32M
Operating Profit USD -165.55M
Ordinary Share Capital USD 138.14M
PE Price to Earnings USD 436.79
Pre-Tax Profit USD -179.09M
Sales Revenues USD 27.77M
Selling and Administration Expenses USD 30.95M
Stock USD -173.09M
Trade Creditors USD 33.05M
Trade Debtors USD 9.7M

Assets Change Date
Agios Pharmaceuticals USD 1.47B 84.28M Jun/2025
Alnylam Pharmaceuticals USD 4.57B 352.21M Jun/2025
Arrowhead Research USD 1.38B 192.89M Jun/2025
Incyte USD 5.82B 71.99M Jun/2025
Ionis Pharmaceuticals USD 2.99B 172.18M Jun/2025
Ligand Pharmaceuticals USD 948.6M 43.17M Jun/2025
Merck USD 117.52B 2.4B Jun/2025
Moderna USD 12.01B 694M Jun/2025
Novartis USD 104.4B 4.45B Jun/2025
Sarepta Therapeutics USD 3.68B 214.43M Jun/2025
TG Therapeutics USD 702.61M 45.92M Jun/2025
Ultragenyx Pharmaceutical USD 1.31B 5.66M Jun/2025
Vertex Pharmaceuticals USD 24.04B 1.16B Jun/2025
Xencor USD 879.42M 25.26M Jun/2025